Potential implications of matrix metalloproteinase-9 in assessment and treatment of coronary artery disease

Biomarkers

Volumn 14, Issue 2, 2009, Pages 118-129

  Konstantino, Yuval ^a,b   Nguyen, Tu T ^a   Wolk, Robert ^a   Aiello, Robert J ^a   Terra, Steven G ^a   Fryburg, David A ^a  

^a PFIZER INC   (United States)

^b RABIN MEDICAL CENTER   (Israel)

Author keywords

Acute coronary syndrome; Atherosclerosis; MMP inhibitors; MMP 9; MMPs

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALENDRONIC ACID; ATORVASTATIN; BATIMASTAT; BISPHOSPHONIC ACID DERIVATIVE; CERIVASTATIN; CLODRONIC ACID; DOXYCYCLINE; FLUINDOSTATIN; GELATINASE A; GELATINASE B; GLIMEPIRIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INCYCLINIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; MEVINOLIN; PAMIDRONIC ACID; PIOGLITAZONE; PRINOMASTAT; REBIMASTAT; ROSIGLITAZONE; ROSUVASTATIN; SIMVASTATIN; TETRACYCLINE DERIVATIVE; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TROGLITAZONE; PROTEINASE INHIBITOR;

ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE MARKER; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INHIBITION; DYSLIPIDEMIA; ENZYME ACTIVITY; ENZYME INHIBITION; FLU LIKE SYNDROME; HUMAN; HYPERTENSION; KAPOSI SARCOMA; MEDICAL ASSESSMENT; MORBIDITY; MORTALITY; MUSCULOSKELETAL DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOPOROSIS; OUTCOME ASSESSMENT; PATHOGENESIS; PATHOPHYSIOLOGY; PHOTOSENSITIVITY; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; STABLE ANGINA PECTORIS; ANIMAL; ARTICLE; BLOOD; CORONARY ARTERY DISEASE; DRUG ANTAGONISM; ENZYMOLOGY; METABOLISM; MOUSE; RISK FACTOR;

ANIMALS; CORONARY ARTERY DISEASE; HUMANS; MATRIX METALLOPROTEINASE 9; MICE; PROTEASE INHIBITORS; RISK FACTORS;

EID: 66149133714     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.1080/13547500902765140     Document Type: Review

References (93)

1. Almuti K, Rimawi R, Spevack D, Ostfeld RJ. 2006. Effects of statins beyond lipid lowering: potential for clinical benefits. Int J Cardiol 109:7-15.
2. Beaudeux JL, Giral P, Bruckert E, Bernard M, Foglietti MJ, Chapman MJ. 2003. Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1 as potential markers of carotid atherosclerosis in infraclinical hyperlipidemia. Atherosclerosis 169:139-146.
3. Beaudeux JL, Giral P, Bruckert E, Foglietti MJ, Chapman MJ. 2004. Matrix metalloproteinases, inflammation and atherosclerosis: Therapeutic perspectives. Clin Chem Lab Med 42:121-131.
4. Bellosta S, Via D, Canavesi P, Pfister R, Fumagalli R, Paoletti R, Bernini F. 1998. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 18:1671-1678.
5. Bendeck MP. 2004. Macrophage matrix metalloproteinase-9 regulates angiogenesis in ischemic muscle. Circ Res 94:138-139.
6. Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G, Meyer J, Cambien F, Tiret L. 2003. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 107:1579-1585.
7. Blaschke F, Spanheimer R, Khan M, Law RE. 2006. Vascular effects of TZDs: new implications. Vasc Pharmacol 45:3-18.
8. Brown DL, Hibbs MS, Kearney M, Loushin C, Isner JM. 1995. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. Circulation 91:2125-2131.
9. Calnek DS, Mazzella L, Roser S, Roman J, Hart CM. 2003. Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol 23:52-57.
10. Castrillo A, Joseph SB, Marathe C, Mangelsdorf DJ, Tontonoz P. 2003. Liver X receptor-dependent repression of matrix metalloproteinase- 9 expression in macrophages. J Biol Chem 278:10443-10449.
11. Cheng M, Hashmi S, Mao X, Zeng QT. 2008. Relationships of adiponectin and matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase- 1 ratio with coronary plaque morphology in patients with acute coronary syndrome. Can J Cardiol 24:385-390.
12. Cuccurullo C, Iezzi A, Fazia ML, De Cesare D, Di Francesco A, Muraro R, Bei R, Ucchino S, Spigonardo F, Chiarelli F, Schmidt AM, Cuccurullo F, Mezzetti A, Cipollone F. 2006. Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol 26:2716-2723.
13. Curci JA, Liao S, Huffman MD, Shapiro SD, Thompson RW. 1998. Expression and localization of macrophage elastase matrix metalloproteinase- 12 in abdominal aortic aneurysms. J Clin Invest 102:1900-1910.
14. de Nooijer R, Verkleij CJ, von der Thusen JH, Jukema JW, van der Wall EE, van Berkel JC, Baker AH, Biessen AL. 2006. Lesional overexpression of matrix metalloproteinase-9 promotesintraplaque hemorrhage in advanced lesions but not at earlier stages of atherogenesis. Arterioscler Thromb Vasc Biol 26:340-346.
15. Death AK, Fisher EJ, McGrath KCY, Yue DK. 2003. High glucose alters matrix metalloproteinase expression in two key vascular cells: potential impact on atherosclerosis in diabetes. Atherosclerosis 168:263-269.
16. Deguchi JO, Aikawa M, Tung CH, Aikawa E, Kim DE, Ntziachristos V, Weissleder R, Libby P. 2006. Inflammation in atherosclerosis: visualizing matrix metalloproteinase action in macrophages in vivo. Circulation 114:55-62.
17. Delclaux C, Delacourt C, D'Ortho MP, Boyer V, Lafuma C, Harf A. 1996. Role of gelatinase B and elastase in human polymorphonuclear neutrophil migration across basement membrane. Am J Respir Cell Mol Biol 14:288-295.
18. Derosa G, D' Angelo A Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo S, Montagna L, Gravina A, Ferrari I, Galli S, Paniga S, Tinelli C, Cicero AF. 2006. Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension. Endothelium 13:227-231.
19. Dollery CM, McEwan JR, Henney AM. 1995. Matrix metalloproteinases and cardiovascular disease. Circ Res 77:863-868.
20. Dormandy J, Charbonnel B, Eckland D, Erdmann E, Massi-Benedetti M, Moules I, Skene A, Tan M, Lefèbvre P, Murray G. 2005. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study PROspective pioglitAzone Clinical Trial In macroVascular Events: A randomised controlled trial. Lancet 366:1279-1289.
21. Douillard JY, Peschel C, Shepherd F, Paz-Ares L, Arnold A, Davis M, Tonato M, Smylie M, Tu D, Voi M, Humphrey J, Ottaway J, Young K, Vreckem AV, Seymour L. 2004. Randomized phase II feasibility study of combining the matrix metalloproteinase inhibitor BMS-275291 with paclitaxel plus carboplatin in advanced non-small cell lung cancer. Lung Cancer 46:361-368.
22. Eldrup N, Gronholdt ML, Sillesen H, Nordestgaard BG. 2006. Elevated matrix metalloproteinase-9 associated with stroke or cardiovascular death in patients with carotid stenosis. Circulation 114:1847-1854.
23. Fife RS, Sledge GW Jr. 1995. Effects of doxycycline on in vitro growth, migration, and gelatinase activity of breast carcinoma cells. J Lab Clin Med 125:407-411.
24. Fukuda D, Shimada K, Tanaka A, Kusuyama T, Yamashita H, Ehara S, Nakamura Y, Kawarabayashi T, Iida H, Yoshiyama M, Yoshikawa J. 2006. Comparison of levels of serum matrix metalloproteinase- 9 in patients with acute myocardial infarction versus unstable angina pectoris versus stable angina pectoris. Am J Cardiol 97:175-180.
25. Funayama H, Ishikawa SE, Kubo N, Katayama T, Yasu T, Saito M, Kawakami M. 2004. Increases in interleukin-6 and matrix metalloproteinase- 9 in the infarct-related coronary artery of acute myocardial infarction. Circ J 68:451-454.
26. Galis ZS, Khatri JJ. 2002. Matrix metalloproteinases in vascular remodeling and atherogenesis: The good, the bad, and the ugly. Circ Res 90:251-262.
27. Galis ZS, Sukhova GK, Lark MW, Libby P. 1994. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 94:2493-2503.
28. Goldstein JA, Demetriou D, Grines CL, Pica M, Shoukfeh M, O'Neill WW. 2000. Multiple complex coronary plaques in patients with acute myocardial infarction. N Engl J Med 343:915-922.
29. Gough PJ, Gomez IG, Wille PT, Raines EW. 2006. Macrophage expression of active MMP-9 induces acute plaque disruption in apoEdeficient mice. J Clin Invest 116:59-69.
30. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. 2002. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106:679-684.
31. Hanemaaijer R, Visser H, Koolwijk P, Sorsa T, Salo T, Golub LM, van Hinsbergh VWM. 1998. Inhibition of MMP synthesis by doxycycline and chemically modified tetracyclines CMTs in human endothelial cells. Adv Dent Res 12:114-118.
32. Hasty KA, Pourmotabbed TF, Goldberg GI, Thompson JP, Spinella DG, Stevens RM, Mainardi CL. 1990. Human neutrophil collagenase. A distinct gene product with homology to other matrix metalloproteinases. J Biol Chem 265:11421-11424.
33. Hidalgo M, Eckhardt SG. 2001. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 93:178-193. (Pubitemid 32166488)
34. Jackson LA, Smith NL, Heckbert SR, Grayston JT, Siscovick DS, Psaty BM. 2000. Past use of erythromycin, tetracycline, or doxycycline is not associated with risk of first myocardial infarction. J Infect Dis 181 (Suppl. 3):S563-S565.
35. Jacqueminet S, Ben Abdesselam O, Chapman MJ, Nicolay N, Foglietti MJ, Grimaldi A, Beaudeux JL. 2006. Elevated circulating levels of matrix metalloproteinase-9 in type 1 diabetic patients with and without retinopathy. Clin Chim Acta 367:103-107.
36. Johnson JL, George SJ, Newby AC, Jackson CL. 2005. Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries. Proc Natl Acad Sci U S A 102:15575-15580.
37. Kai H, Ikeda H, Yasukawa H, Kai M, Seki Y, Kuwahara F, Ueno T, Sugi K, Imaizumi T. 1998. Peripheral blood levels of matrix metalloproteases- 2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 32:368-372.
38. Kardara M, Papazafiropoulou A, Katsakiori P, Petropoulos C, Jelastopulu E. 2006. Protective effect of doxycycline use on coronary artery disease? J Infect 52:243-246.
39. Kelly MA, Shuaib A, Todd KG. 2006. Matrix metalloproteinase activation and blood-brain barrier breakdown following thrombolysis. Exp Neurol 200:38-49.
40. Kramsch DM, Aspen AJ, Rozler LJ. 1981. Atherosclerosis: Prevention by agents not affecting abnormal levels of blood lipids. Science 213:1511-1512.
41. Kramsch DM, Chan CT. 1978. The effect of agents interfering with soft tissue calcification and cell proliferation on calcific fibrous-fatty plaques in rabbits. Circ Res 42:562-571.
42. Lara PN Jr, Stadler WM, Longmate J, Quinn DI, Wexler J, van Loan M, Twardowski P, Gumerlock PH, Vogelzang NJ, Vokes EE, Lenz HJ, Doroshow JH, Gandara DR. 2006. A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone- refractory prostate cancer patients with bone metastases. Clin Cancer Res 12:1556-1563.
43. Laufs U, Liao JK. 2000. Direct vascular effects of HMG-CoA reductase inhibitors. Trends Cardiovasc Med 10:143-148.
44. Leighl NB, Paz-Ares L, Douillard JY, Peschel C, Arnold A, Depierre A, Santoro A, Betticher DC, Gatzemeier U, Jassem J, Crawford J, Tu D, Bezjak A, Humphrey JS, Voi M, Galbraith S, Hann K, Seymour L, Shepherd FA. 2005. Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18. J Clin Oncol 23):2831-2839.
45. Leu HB, Chen JW, Wu TC, Ding YA, Lin SJ, Charng MJ. 2005. Effects of fluvastatin, an HMG-CoA reductase inhibitor, on serum levels of interleukin-18 and matrix metalloproteinase-9 in patients with hypercholesterolemia. Clin Cardiol 28:423-428.
46. Li-Saw-Hee FL, Edmunds E, Blann AD, Beevers DG, Lip GY. 2000. Matrix metalloproteinase-9 and tissue inhibitor metalloproteinase-1 levels in essential hypertension. Relationship to left ventricular mass and anti-hypertensive therapy. Int J Cardiol 75:43-47.
47. Lindsey ML, Escobar GP, Dobrucki LW, Goshorn DK, Bouges S, Mingoia JT, McClister DM Jr, Su H, Gannon J, MacGillivray C, Lee RT, Sinusas AJ, Spinale FG. 2006. Matrix metalloproteinase-9 gene deletion facilitates angiogenesis after myocardial infarction. Am J Physiol Heart Circ Physiol 290:H232-H239.
48. Loftus IM, Naylor AR, Goodall S, Crowther M, Jones L, Bell PR, Thompson MM. 2000. Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption. Stroke 31:40-47.
49. Luan Z, Chase AJ, Newby AC. 2003. Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol 23:769-775.
50. Luttun A, Lutgens E, Manderveld A, Maris K, Collen D, Carmeliet P, Moons L. 2004. Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth. Circulation 109:1408-1414.
51. Manginas A, Bei E, Chaidaroglou A, Degiannis D, Koniavitou K, Voudris V, Pavlides G, Panagiotakos D, Cokkinos DV. 2005. Peripheral levels of matrix metalloproteinase-9, interleukin-6, and C-reactive protein are elevated in patients with acute coronary syndromes: Correlations with serum troponin I. Clin Cardiol 28:182-186.
52. Mao D, Lee JK, VanVickle SJ, Thompson RW. 1999. Expression of collagenase-3 MMP-13 in human abdominal aortic aneurysms and vascular smooth muscle cells in culture. Biochem Biophys Res Commun 261:904-910.
53. Marx N, Froehlich J, Siam L, Ittner J, Wierse G, Schmidt A, Scharnagl H, Hombach V, Koenig W. 2003. Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 23:283-288.
54. Marx N, Sukhova G, Murphy C, Libby P, Plutzky J. 1998. Macrophages in human atheroma contain PPARgamma: differentiation- dependent peroxisomal proliferator-activated receptor gamma (PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. Am J Pathol 153:17-23.
55. Mauriello A, Sangiorgi G, Fratoni S, Palmieri G, Bonanno E, Anemona L, Schwartz RS, Spagnoli LG. 2005. Diffuse and active inflammation occurs in both vulnerable and stable plaques of the entire coronary tree: A histopathologic study of patients dying of acute myocardial infarction. J Am Coll Cardiol 45:1585-1593.
56. Maxwell PR, Timms PM, Chandran S, Gordon D. 2001. Peripheral blood level alterations of TIMP-1, MMP-2 and MMP-9 in patients with type 1 diabetes. Diabet Med 18:777-780.
57. Miller KD, Saphner TJ, Waterhouse DM, Chen TT, Rush-Taylor A, Sparano JA, Wolff AC, Cobleigh MA, Galbraith S, Sledge GW. 2004. A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast cancer. Clin Cancer Res 10:1971-1975.
58. Nagase H, Visse R, Murphy G. 2006. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 69:562-573.
59. Nakamura T, Ebihara I, Shimada N, Koide H. 1998. Effect of cigarette smoking on plasma metalloproteinase-9 concentration. Clin Chim Acta 276:173-177.
60. Neville-Webbe HL, Holen I, Coleman RE. 2002. The anti-tumour activity of bisphosphonates. Cancer Treat Rev 28:305-319.
61. Noji Y, K. Kajinami, et al. 2001. Circulating matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis. Clin Chem Lab Med 39(5): 380-384
62. Opdenakker G, Van den Steen PE, Dubois B, Nelissen I, Van Coillie E, Masure S, Proost P, Van Damme J. 2001. Gelatinase B functions as regulator and effector in leukocyte biology. J Leukoc Biol 69:851-859.
63. Patel L, Charlton SJ, Marshall IC, Moore GB, Coxon P, Moores K, Clapham JC, Newman SJ, Smith SA, Macphee CH. 2002. PPARgamma is not a critical mediator of primary monocyte differentiation or foam cell formation. Biochem Biophys Res Commun 290:707-712.
64. Pavlaki M, Zucker S. 2003. Matrix metalloproteinase inhibitors MMPIs): The beginning of phase I or the termination of phase III clinical trials. Cancer Metastasis Rev 22:177-203.
65. Pfutzner A, Marx N, Lübben G, Langenfeld M, Walcher D, Konrad T, Forst T. 2005. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 45:1925-1931.
66. Qu HY, Xiao YW, Jiang GH, Wang ZY, Zhang Y, Zhang M. 2008. Effect of Atorvastatin Versus Rosuvastatin on Levels of Serum Lipids, Inflammatory Markers and Adiponectin in Patients with Hypercholesterolemia. Pharm Res Dec 10 [Epub ahead of print].
67. Raffetto JD, Khalil RA 2008. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol 75:346-359.
68. Rekhter MD. 1999. Collagen synthesis in atherosclerosis: Too much and not enough. Cardiovasc Res 41:376-384.
69. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E. 2005. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352:20-28.
70. Rioufol G, Finet G, Ginon I, Andre-Fouet X, Rossi R, Vialle E, Desjoyaux E, Convert G, Huret JF, Tabib A. 2002. Multiple atherosclerotic plaque rupture in acute coronary syndrome: A three-vessel intravascular ultrasound study. Circulation 106:804-808.
71. Rodriguez JA, Orbe J, Martinez de Lizarrondo S, Calvayrac O, Rodriguez C, Martinez-Gonzalez J, Paramo JA. 2008. Metalloproteinases and atherothrombosis: MMP-10 mediates vascular remodeling promoted by inflammatory stimuli. Front Biosci 13:2916-2921.
72. Scatena R. 2000. Prinomastat, a hydroxamate-based matrix metalloproteinase inhibitor. A novel pharmacological approach for tissue remodelling-related diseases. Expert Opin Investig Drugs 9:2159-2165.
73. Schonbeck U, Mach F, Sukhova GK, Atkinson E, Levesque E, Herman M, Graber P, Basset P, Libby P. 1999. Expression of stromelysin-3 in atherosclerotic lesions: regulation via CD40-CD40 ligand signaling in vitro and in vivo. J Exp Med 189:843-853.
74. Squire IB, Evans J, Ng LL, Loftus IM, Thompson MM. 2004. Plasma MMP-9 and MMP-2 following acute myocardial infarction in man: Correlation with echocardiographic and neurohumoral parameters of left ventricular dysfunction. J Card Fail 10:328-333.
75. Staels B, Fruchart JC. 2005. Therapeutic roles of peroxisome proliferator- activated receptor agonists. Diabetes 54:2460-2470.
76. Starckx S, Van den Steen PE, Wuyts A, van Damme J, Opdenakker G. 2002. Neutrophil gelatinase B and chemokines in leukocytosis and stem cell mobilization. Leuk Lymphoma 43:233-241.
77. Sternlicht MD, Werb Z. 2001. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17:463-516.
78. Stintzing S, Heuschmann P, Barbera L, Ocker M, Jung A, Kirchner T, Neureiter D. 2005. Overexpression of MMP9 and tissue factor in unstable carotid plaques associated with Chlamydia pneumoniae, inflammation, and apoptosis. Ann Vasc Surg 19:310-319.
79. Sundstrom J, Evans JC, Benjamin EJ, Levy D, Larson MG, Sawyer DB, Siwik DA, Colucci WS, Sutherland P, Wilson PWF, Vasan RS. 2004. Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: The Framingham Heart Study. Circulation 109:2850-2856. (Pubitemid 38786446)
80. Sundstrom J, Vasan RS 2006. Circulating biomarkers of extracellular matrix remodeling and risk of atherosclerotic events. Curr Opin Lipidol 17:45-53.
81. Tayebjee MH, Lip GYH, Macfadyen RJ. 2005a. Matrix metalloproteinases in coronary artery disease: Clinical and therapeutic implications and pathological significance. Curr Med Chem 12:917-925.
82. Tayebjee MH, Lip GYH, Tan KT, Patel JV, Hughes EA, Macfadyen RJ. 2005b. Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD40 ligand levels in patients with stable coronary artery disease. Am J Cardiol 96:339-345.
83. Tayebjee MH, Nadar S, Blann AD, Beevers DG, Macfadyen RJ, Lip GYH. 2004a. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: A substudy of the Anglo- Scandinavian Cardiac Outcomes Trial ASCOT. Am J Hypertens 17:764-769.
84. Tayebjee MH, Nadar SK, Macfadyen RJ, Lip GYH. 2004b. Tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase- 9 levels in patients with hypertension Relationship to tissue Doppler indices of diastolic relaxation. Am J Hypertens 17:770-774.
85. Teronen O, Heikkila P, Konttinen YT, Laitinen M, Salo T, Hanemaaijer R, Teronen A, Maisi P, Sorsa T. 1999. MMP inhibition and downregulation by bisphosphonates. Ann N Y Acad Sci 878:453-465.
86. Thompson MM, Squire IB 2002. Matrix metalloproteinase-9 expression after myocardial infarction: physiological or pathological? Cardiovasc Res 54:495-498.
87. Turu MM, Krupinski J, Catena S, Resell A, Montaner J, Rubio F, Alvarez-Sabin J, Cairols M, Badimon L. 2006. Intraplaque MMP-8 levels are increased in asymptomatic patients with carotid plaque progression on ultrasound. Atherosclerosis 187:161-169.
88. Tziakas DN, Chalikias GK, Parissis JT, Hazinikolaou EI, Papadopoulos ED, Tripsiannis GA, Papadopoulou EG, Tentes IK, Karas SM, Chatseras DI. 2004. Serum profiles of matrix metalloproteinases and their tissue inhibitor in patients with acute coronary syndromes. The effects of short-term atorvastatin administration. Int J Cardiol 94:269-277.
89. Wilson WR, Anderton M, Schwalbe EC, Jones JL, Furness PN, Bell PR, Thompson MM. 2006. Matrix metalloproteinase-8 and -9 are increased at the site of abdominal aortic aneurysm rupture. Circulation 113:438-445.
90. Xu Z, Zhao S, Zhou H, Ye H, Li J. 2004. Atorvastatin lowers plasma matrix metalloproteinase-9 in patients with acute coronary syndrome. Clin Chem 50:750-753.
91. Zeng B, Prasan A, Fung KC, Solanki V, Bruce D, Freedman SB, Brieger D. 2005. Elevated circulating levels of matrix metalloproteinase- 9 and -2 in patients with symptomatic coronary artery disease. Intern Med J 35:331-335.
92. Zervoudaki A, Economou E, Pitsavos C, Vasiliadou K, Aggeli C, Tsioufis K, Toutouza M, Stefanadis C, Toutouzas P. 2004. The effect of Ca2+ channel antagonists on plasma concentrations of matrix metalloproteinase-2 and -9 in essential hypertension. Am J Hypertens 17:273-276.
93. Zucker S, Cao J, Chen WT. 2000. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 19:6642-16450